Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics Announces Reverse Stock Split
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
Oncternal Therapeutics, Inc. (ONCT) Q3 2023 Earnings Call Transcript
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
Oncternal Therapeutics, Inc. (ONCT) Q1 2023 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny Stocks To Buy? 7 Under $1 To Watch This Week
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway
Why Is Oncternal Therapeutics (ONCT) Stock Down 62% Today?
Oncternal Therapeutics, Inc. (ONCT) Q4 2022 Earnings Call Transcript
Oncternal Therapeutics: Making Progress And Still In Buy Territory
Oncternal Therapeutics, Inc. (ONCT) Q3 2022 Earnings Call Transcript
Oncternal Therapeutics (ONCT) Reports Q3 Loss, Misses Revenue Estimates
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022